The clean double in price of Inhibitex (INHX +131%) following its hepatitis C treatment...

|By:, SA News Editor

The clean double in price of Inhibitex (INHX +131%) following its hepatitis C treatment breakthrough could be sustaining, according to Deutsche's Robyn Karnauskas, who says a "near-term catalyst" is now in play for the firm. Shares of Pharmasset (VRUS) trail off 5% on the news, as the drug from Inhibitex shows a similar efficacy to the company's own treatment.